ENYO Pharma is a clinical-stage biopharmaceutical company developing VONAFEXOR, a small molecule with fibrolytic and anti-inflammatory properties, for the treatment of rare kidney diseases such as Alport Syndrome and Chronic Kidney Disease. The company aims to improve the quality of life for patients with impaired kidney function by targeting the underlying inflammation and fibrosis in these conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Alport Syndrome and Chronic Kidney Disease (CKD) are rare kidney diseases characterized by inflammation and fibrosis, leading to impaired kidney function and reduced quality of life for affected patients. Current treatments often fail to address the underlying mechanisms of these conditions.
Solution
ENYO Pharma is developing VONAFEXOR, a small molecule with fibrolytic and anti-inflammatory properties, as a therapeutic for rare kidney diseases. VONAFEXOR targets the underlying inflammation and fibrosis present in conditions like Alport Syndrome and CKD. The company is currently in Phase 2 clinical development, advancing VONAFEXOR as a highly differentiated therapeutic to improve the quality of life for patients with impaired kidney function.
Target Audience
The primary target audience includes patients suffering from rare kidney diseases such as Alport Syndrome and Chronic Kidney Disease (CKD).
Features
- VONAFEXOR: A small molecule with both fibrolytic and anti-inflammatory properties.
- Phase 2 clinical development for Alport Syndrome.
- Potential application for Chronic Kidney Diseases (CKD), NASH and DKD.